BUZZ-Zydus Lifesciences gains on agreement with CVS Health subsidiary

** Shares of Zydus Lifesciences ZYDU.NS rise about 4% to 999.65 rupees

** Stock second-biggest gainer on the Nifty pharma sub index .NIPHARM, which is up 0.76%

** Co signs an agreement with U.S. based CVS Health's CVS.N subsidiary CVS Caremark to add 3 tablets to CVS Caremark's template formulary

** Formulary indicates a list of prescription medicines covered by a health insurance plan

** Tablets contain active ingredients that improve glycemic control in adults with type 2 diabetes

** ZYDU rated 'hold' on avg, among 11 stocks out of 20 on pharma index with this rating - LSEG

** Stock extends 12-month gain to around 40%, compared to a ~33% jump in pharma sub index in same period

(Reporting by Ananta Agarwal in Bengaluru)

((Ananta.Agarwal@thomsonreuters.com))